Follow this forum via email Follow this innovation hub [ via ] [?]
Innovation Hub

Pediatric

"In seeking to provide the highest quality care to their patients, pediatric clinicians and institutions are often limited by available devices or drugs that have not been optimized for the treatment of children. This shortfall in child-appropriate medical devices and drug formulations represents a significant opportunity to effect positive change." - Institute for Pediatric Innovation


The Latest Innovations
Children's Hospital Boston

10 FEB 12

A Transgenic Zebrafish model for Melanoma using BRAF and other cell cycle mutan

This work has created a zebrafish model of both benign nevi and malignant melanoma, a model that offers faithful recreation of the human melanomagenesis and attractive adaptability for investigative research. Transgenic zebrafish bearing human, mutated BRAF (V599E) cDNA, expressed in under the m...

Washington State University

08 FEB 12

Infant Remote Respiratory Apparatus and Methods

Preterm delivery, which occurs in 8-10 percent of all pregnancies in the US, is the frequent cause of deaths among infants. Premature infants or preemies require special care and spend weeks or months hospitalized in a neonatal intensive care unit (NICU). While at NICU, many of these infants are ...

Washington State University

08 FEB 12

Proximity Dependent Inhibitory Mechanism Identified in Eschiricia coli Isolated from Cattle

Harmful strains of Eschiricia coli bacteria, primarily found in cattle cause severe, sometimes life-threatening human illness. According to the US' Centers for Disease Control and Prevention, an estimated 110,000 cases (due to specifically enterohaemorrhagic E. coli (EHEC)) occur annually in the ...

Washington State University

08 FEB 12

Erupt-a-Cake

This all-natural, ready-to-bake chocolate cake sports an erupting volcano (with flavored lava), island-theme decorations, and gummy dinosaurs. The target audience for Erupt-a-Cake is 'tweens' aged 8 – 12 years old. This new product will not only excite children's eyes and provide unforgettable ...

Emory

28 JAN 12

Small Molecule Non-Nucleoside Inhibitors of the Measles Viruses

Application Small molecule measles virus RNA Dependent RNA Polymerase (RDRP) inhibitors. Highlights Potent (nM) non-nucleoside small molecule inhibitors of the measles virus RDRP protein. No current drug therapy for measles. Market Summary The target market for this therape...

UCSD TTO

19 JAN 12

Compositions and Methods for Tympanic Membrane Transmigration

<p>Otitis media is one of the most common diseases of childhood, resulting in more physician visits and surgeries than any other pediatric disorder. Persistent or recurrent otitis media can damage the middle or inner ear and cause permanent hearing loss. There exists a need to identify target...

UWMRF

13 JAN 12

Automatic Pathology Software for Diagnosis of Non-Alcoholic Fatty Liver Disease

The invention is a supervised machine learning approach for automatically classifying “white-regions” of liver biopsies into 1 of 7 categories, thus providing an important decision support system for pathologists. White-region classification can be applied in multiple analyses performed on liver ...

Children's Hospital Boston

09 JAN 12

Fibromodulin for the treatment of age related macular degeneration

Dr. Robert D'Amato and his fellow Dr. Irit Adini discovered fibromodulin, a known small interstitial proteoglycan, as a novel pro- angiogenic factor produced by melanocytes that regulates blood vessel formation in pigmented tissues such as the skin and eyes. They showed that low pigmented cells...

Children's Hospital Boston

07 JAN 12

miRNA-135a to detect and reverse taxane resistance in tumor cells

Dr. Zetter's lab screened taxane-resistant tumor cells and taxane-sensitive cells for differences in miRNA expression. They identified miR-135a as being upregulated in resistant tumor cells relative to sensitive cells. Cancer types tested included prostate cancer, breast cancer and uterine carcin...

University of Pittsburgh

06 JAN 12

Novel Immune Modulatory Agent in the Treatment of Neonatal Necrotizing Enterocolitis (NEC) and other inflammatory disorders

<p>Investigators at the University of Pittsburgh have identified a novel <span class="caps">TLR</span>-4 antagonist to treat <span class="caps">NEC</span> which is highly effective in animal models. This antagonist is also effective in other TLR4-mediated diseases including trauma and hemorrhagic...

See All 497 innovations


Organizations
Followed By

Other Hubs

Autism

Cystic Fibrosis

Energy innovation

Parkinson’s disease

Blood-brain barrier

Neglected diseases

Rare diseases

Engineering
Profile
Related Tags

Find more innovations


February 11, 2009

7,854 members 17,202 innovations 152 organizations

Browse

Dr. Jörg Knäblein – Technology Scouting, Bayer Schering Pharma AG

"Through the iBridge Network, I was able to find a mouse model I was looking for. The collaboration available through the iBridge Network is crucial in driving innovation and I'll continue using it as a valued resource."  read more...